| Product NDC: | 66758-046 |
| Proprietary Name: | Fludarabine Phosphate |
| Non Proprietary Name: | Fludarabine Phosphate |
| Active Ingredient(s): | 25 mg/mL & nbsp; Fludarabine Phosphate |
| Administration Route(s): | INTRAVENOUS |
| Dosage Form(s): | INJECTION, SOLUTION |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 66758-046 |
| Labeler Name: | Sandoz Inc |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA022137 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20071012 |
| Package NDC: | 66758-046-01 |
| Package Description: | 1 VIAL, SINGLE-DOSE in 1 CARTON (66758-046-01) > 2 mL in 1 VIAL, SINGLE-DOSE |
| NDC Code | 66758-046-01 |
| Proprietary Name | Fludarabine Phosphate |
| Package Description | 1 VIAL, SINGLE-DOSE in 1 CARTON (66758-046-01) > 2 mL in 1 VIAL, SINGLE-DOSE |
| Product NDC | 66758-046 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Fludarabine Phosphate |
| Dosage Form Name | INJECTION, SOLUTION |
| Route Name | INTRAVENOUS |
| Start Marketing Date | 20071012 |
| Marketing Category Name | NDA |
| Labeler Name | Sandoz Inc |
| Substance Name | FLUDARABINE PHOSPHATE |
| Strength Number | 25 |
| Strength Unit | mg/mL |
| Pharmaceutical Classes | Nucleic Acid Synthesis Inhibitors [MoA],Nucleoside Metabolic Inhibitor [EPC] |